Savlon Antiseptic Liquid

Country: Ireland

Bahasa: Inggeris

Sumber: HPRA (Health Products Regulatory Authority)

Beli sekarang

Download Ciri produk (SPC)
09-08-2016

Bahan aktif:

Cetrimide; Chlorhexidine gluconate

Boleh didapati daripada:

GlaxoSmithKline Consumer Healthcare (Ireland) Limited

Kod ATC:

D08AJ; D08AJ04

INN (Nama Antarabangsa):

Cetrimide; Chlorhexidine gluconate

Dos:

2.25%w/v +0.225 percent weight/volume

Borang farmaseutikal:

Concentrate for cutaneous solution

Jenis preskripsi:

Product not subject to medical prescription

Kawasan terapeutik:

Quaternary ammonium compounds; cetrimide

Status kebenaran:

Not marketed

Tarikh kebenaran:

1991-06-26

Ciri produk

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Savlon Antiseptic Liquid.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Cetrimide 2.25 % w/v and Chlorhexidine Gluconate 0.225 % w/v.
Excipients: also includes benzyl benzoate 0.056% w/v
For a full list excipients, see Section 6.1.
3 PHARMACEUTICAL FORM
Concentrate for Cutaneous Solution.
A clear, colourless or almost colourless liquid with a pine-like
odour.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
A topical antiseptic for prevention and management of infection or
superficial skin trauma.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
For cutaneous use.
Two capfuls to ½ litre of warm water.
4.3 CONTRAINDICATIONS
Hypersensitivity to chlorhexidine, cetrimide or to any of the
excipients listed in Section 6.1.
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
If symptoms persist or condition worsens or if a skin reaction occurs,
discontinue use and consult a doctor.
For external use only.
Avoid contact with the eyes, ears, mouth or other mucosa.
If accidentally splashed into the eye, the open eye should be
irrigated with water for at least 10 minutes.
Savlon Antiseptic Liquid contains benzyl benzoate which may be mildly
irritant to the skin, eyes and mucous
membranes.
4.5 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF
INTERACTION
No interaction studies have been performed with the topical forms.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_5_
_/_
_0_
_7_
_/_
_2_
_0_
_1_
_6_
_C_
_R_
_N_
_ _
_2_
_1_
_
                                
                                Baca dokumen lengkap